Evaluation of Bridge Capture technology for mutation profiling in liquid biopsies of metastatic colorectal cancer patients.

ABSTRACT: Colorectal cancer (CRC) is the second leading cause of cancer-related deaths, often presenting at an advanced stage with significant molecular heterogeneity. This is the first study to evaluate the performance of a novel next-generation sequencing (NGS)-based Bridge Capture technology for mutation profiling and minimal residual disease detection in circulating tumor (ct)DNA from metastatic colorectal cancer (mCRC) patients. Its performance was compared to those of droplet digital PCR (ddPCR), Ion AmpliSeq Cancer Hotspot Panel v2, and Idylla ctKRAS Mutation Assay. Eighty serial plasma samples from ten mCRC patients were analyzed by Bridge Capture and ddPCR, demonstrating a very strong correlation in variant allele frequency (VAF) values (r_s = 0.86). The concordance of Bridge Capt

SUBMITTER: Ganesan A 

PROVIDER: S-EPMC12218867 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature